Trump, Novartis and Drug Prices
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that ...
According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
13d
GlobalData on MSNNovartis signs agreement to acquire Anthos for $925m upfrontNovartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...
Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of young entrepreneurs.
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results